92 results about "Bacillus isolates" patented technology

The present invention pertains to a method to isolate, separate, enrich or amplify a targeted nucleotide polymer such as mRNA through selective reverse transcription of the targeted polymer into cDNA from a sample comprising of chemically identical or similar polynucleotide polymers such as rRNA. The enrichment of the targeted nucleic acid such as mRNA is accomplished by blocking the reverse transcription of undesired rRNA while allowing unrestricted reverse transcription of the targeted polymer. The invention also embodies that the cleavage of the non-targeted nucleic acid such as rRNA bound to an oligonucleotide through enzymatic activity (RNase H). The invention further embodies methods and kits to accomplish the utility of the invention through the following steps 1) 3′ tailing of chemically identical or similar nucleotide polymers in a sample that includes bacterial mRNA 2) a 3′ tail capable of binding to a oligo-dN primer 3) at least one oligonucleotide capable of preventing the extension of oligo-dN bound to at least one non-targeted nucleotide polymers by a DNA polymerase such as a reverse transcriptase without restricting conversion of bacterial mRNA into cDNA 4) where the non-targeted molecule is prevented as a template for cDNA synthesis by enzymatic cleavage (RNase H) of template (rRNA)-oligonucleotide hybrid 5) where the reverse transcriptase is physically blocked by the oligonucleotide bound to the non-targeted nucleic acids such as rRNA 5) purification of the selectively transcribed cDNA. In further embodiments of the present invention, methods and composition to enable the study of bacterial transcriptomics-an analysis of genes expressed by a bacterial infection of a host, an isolated bacterial culture or a bacterial community, such as recovered from soil, intestine, mouth, biofilm, water etc are also included for use in DNA-chip or sequencing analyses.

Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and/or probes) and identified (species-specific primers and/or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and/or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

Methods of inducing systemic acquired resistance to infection in a plant are provided. The methods comprise applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins. Also provided are, methods for controlling one or more plant diseases, methods for preventing plant virus transmission, methods for preventing and/or treating soil-borne plant pathogens using the Bacillus control agent of the present invention, and methods of generating bacterial spores. In addition, synergistic biocontrol combinations and methods of using the same are provided.

Disclosed is an isolated bacterial strain Candidatus Brocadia caroliniensis strain, having Accession Deposit Number NRRL B-50286. The strain is capable of oxidizing ammonium and releasing di-nitrogen gas.

This application describes and claims a method of improving the health and vigor of a plant, comprising administering to the plant an effective amount of a bacterial composition which comprises a botanically compatible vehicle and an isolated bacterial strain selected from the group consisting of Bacillus megaterium PT6, Bacillus subtilis PT26A, Paenibacillus sp. ATY16, and any combination thereof. Improvement in health and vigor is one or more of the following: a) improved resistance to disease; b) improved ability to defend against disease; c) reduction of disease symptoms; d) faster growth; e) improved crop productivity; f) improved crop quality; g) improved seed germination; h) improved seedling emergence; or any combination thereof. Isolated bacterial strains and mixtures of bacteria are provided, as well as compositions comprising the isolated bacterial strains.

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. With these methods, bacteria can be detected (universal primers and/or probes) and identified (species-specific primers and/or probes) directly from the clinical specimens or from an isolated bacterial colony. Bacteria are further evaluated for their putative susceptibility to antibiotics by resistance gene detection (antibiotic resistance gene specific primers and/or probes). Diagnostic kits for the detection of the presence, for the bacterial identification of the above-mentioned bacterial species and for the detection of antibiotic resistance genes are also claimed. These kits for the rapid (one hour or less) and accurate diagnosis of bacterial infections and antibiotic resistance will gradually replace conventional methods currently used in clinical microbiology laboratories for routine diagnosis. They should provide tools to clinicians to help prescribe promptly optimal treatments when necessary. Consequently, these tests should contribute to saving human lives, rationalizing treatment, reducing the development of antibiotic resistance and avoid unnecessary hospitalizations.

The invention relates to a method for separating Aeromonas molluscorum producing tetrodotoxin from Takifugu fasciatus tissues and a fermentation culture method of the Aeromonas molluscorum as well as a detection method of the produced tetrodotoxin. The method for separating the Aeromonas molluscorum producing the tetrodotoxin from the Takifugu fasciatus tissues comprises a bacteria separation method, a bacteria identification method, a bacteria fermentation culture method, a competitiveness ELISA (Enzyme Linked Immunosorbent Assay) detection method and an LC-MS (Liquid Chromatograph-mass Spectrometry) detection method of the tetrodotoxin produced by the Aeromonas molluscorum, and the like. In the invention, by separating bacteria from Takifugu fasciatus ovaries and adopting a TCBS (Thiosulfate Citrate Bile (salt) Sucrose (agar)) culture medium for screening, the Aeromonas molluscorum capable of producing the tetrodotoxin is separated from blowfish bodies for the first time; the separated bacteria is identified by adopting a 16 SrDNA method; the competitiveness ELISA detection method and the LC-MS detection method are both firstly adopted for the tetrodotoxin produced by the separated Aeromonas molluscorum; and the produced tetrodotoxin and tetrodotoxin extracted from the blowfish bodies are determined to be the same substance; in addition, the separated Aeromonas molluscorum can massively separate the tetrodotoxin from the bacteria after being cultured.

The present disclosure relates to isolated bacterial strains producing polyhydroxyalkanoate (PHA), microbial consortia including such strains, and cultures of such strains and microbial consortia. In particular, the present disclosure relates to compositions including such strains, microbial consortia, and cultures and methods of use thereof.

Compositions of bacteria which are effective for the nitrification of wastewater, particularly at low temperatures, are described. The compositions are comprised of 35 strains or populations of at least partially characterized isolated bacteria. These compositions may be used to treat wastewater contaminated with animal fecal waste and/or ammonia. In use, wastewater is contacted with the bacterial composition of the invention under aerobic conditions and for a period of time effective to oxidize ammonia therein.

The invention discloses a bacterial cellulose nanofiber composite membrane for efficient protein adsorption and separation and a preparation method of the composite membrane. The preparation method comprises the steps as follows: a bacterial cellulose membrane is mechanically dissociated into bacterial cellulose nanofiber; the surface of the bacterial cellulose nanofiber is modified with an adsorption functional group; the modified bacterial cellulose nanofiber is dispersed in an insoluble solvent, and a stable bacterial cellulose nanofiber suspension is formed by adding a dispersant; the bacterial cellulose nanofiber suspension is laid on the surface of a porous fiber base material with a synchronous ultrasonic filtration method to form a wet-state composite fiber membrane; the residual solvent in the wet-state composite fiber membrane is removed and the bacterial cellulose nanofiber composite membrane for efficient protein adsorption and separation can be obtained. A completely covered continuous two-dimensional net structure formed by the bacterial cellulose nanofiber is arranged on the surface of the composite membrane, meanwhile, a large quantity of adsorption active sites on the surface and high porosity are realized, and quick and effective adsorption of protein is realized, and the adsorption capacity is high.

The invention discloses an infection control management system and method based on artificial intelligence. The system comprises a middleware module, a clinical database module, a strain identification module, an expert system module, a machine learning neural network and a prediction and early warning module; for newly-separated bacteria and a related antibiotic knowledge graph, the expert systemmodule is used for verifying culture results of antibiotics, selecting a suitable antibiotic list and giving an alarm to the newly-separated bacteria; the machine learning neural network is used forlearning and establishing association rules of the bacteria, the antibiotics and an infection part, establishing a specific knowledge graph according to the relationship of the bacteria, the antibiotics and the infection part, and integrating the specific knowledge graph into the expert system module; the prediction and early warning module establishes a prediction model for predicting infection data and an infection trend within a specific range, and when the predicted value of an infection event is higher than a set threshold value, the prediction and early warning module gives an early warning to medical staff and/or a community. The infection control management system and method based on artificial intelligence can achieve automatic monitoring, analysis and real-time early warning of infection cases and infection conditions in the community.

A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral γ₁ 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of γ₁ 34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. Other known syncytial mutations could also be introduced that would render the virus able to cause extensive virus-induced cell fusion. In addition, other known mutations can be introduced to limit the spread of the virus to the nervous system. These altered viruses or the isolated bacterial chromosomes could be used to treat various cancers including breast, liver, colon, and other tissues.

Immobilized cell beads incorporating formulated microbial consortium comprising a synergistic mixture of the following bacterial strains namely, Enterobacter sakazaki, Pseudomonas aeruginosa and Aeromonas sobria selected from the following isolated bacterial strains namely, Yersinia enterocolitica, Aeromonas sobria, Klebsiella pneumoniae, Serratia liquefaciens, Enterobacter sakazaki, Citrobacter amalonaticus, Pseudomonas fluorescens, Pseudomonas aeruginosa, Enterobacter cloaca, Acinetobacter calcoaceticus are prepared, the formulated microbial consortium is immobilized in an appropriate immobilizing agent resulting in the formation of beads and the beads are used for instant BOD estimation using an electronic device and the formulated cell beads are reusable and are capable of assimilating most of the organic matter present in varied industrial effluents.

The invention belongs to the technical field of bacteria separation and particularly relates to multistage bacterial liquid bacteria screening equipment. The multistage bacterial liquid bacteria screening equipment comprises a mounting barrel body, a separation module, an automatic collection module and an anti-pollution module; a temporary storage room is arranged at the upper part of the mounting barrel body and is used for temporary storage of bacteria separated by the separation module; a bacterial liquid release tube is communicated wit the lower end of the temporary storage room and is used for releasing the bacteria in the temporary storage room; the separation module is positioned in the temporary storage room and is used for separating the bacteria of different sizes; the automatic collection module is positioned at the lower end of the bacterial liquid release tube and is used for receiving the bacteria of different sizes released from the bacterial liquid release tube; the anti-pollution module is distributed on the mounting barrel body, the temporary storage room and the separation module and is used for preventing external bacteria or the separated bacteria from polluting bacteria that is being separated. The multistage bacterial liquid bacteria screening equipment provided by the invention can quickly separate in batch and respectively store the various bacteria of different sizes in the bacterial liquid and can improve the bacterial liquid bacteria separation efficiency.

The present disclosure relates generally to the growth of recombinant bacterial cells of photoautotrophic species under diurnal conditions. In particular, the present disclosure relates to isolated bacterial cells of photoautotrophic species having increased growth under diurnal conditions by expression of a sugar transporter protein and methods of use thereof.

A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, wherein the strain is selected from the group consisting of Prevotella copri, Prevotella stercorea, Prevotella histicola, Prevotella ruminicola, Prevotella Bryantii 25A and Prevotella distasonis. The product may be a food product.